Clinical Trial Update: Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating axicabtagene ciloleucel versus standard of care in relapsed/refractory follicular lymphoma is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Axicabtagene ciloleucel (axicabtagene ciloleucel)

Snippet

Sponsor: Kite, A Gilead Company | Conditions: Relapsed/Refractory Follicular Lymphoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING